Cite
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.
MLA
Lee, Ji Yun, et al. “Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.” Cancer Research & Treatment, vol. 56, no. 2, Apr. 2024, pp. 681–87. EBSCOhost, https://doi.org/10.4143/crt.2023.1042.
APA
Lee, J. Y., Kwon, J. H., Hur, J. Y., Yi, J. H., Lee, J. H., Cho, H., Do, Y. R., Jo, J.-C., Kang, H. J., Koh, Y., Lee, W. S., Lim, S. N., Yoon, S. E., Kim, S. J., & Lee, J.-O. (2024). Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea. Cancer Research & Treatment, 56(2), 681–687. https://doi.org/10.4143/crt.2023.1042
Chicago
Lee, Ji Yun, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, et al. 2024. “Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.” Cancer Research & Treatment 56 (2): 681–87. doi:10.4143/crt.2023.1042.